Clinical trials: Acromegaly
Acromegaly
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
An open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are treated with somatostatin analogue (SSA) based treatment…
- Trial name
- NCT03789656
- Testing
- Paltusotine
- Where
- 26 sites in United States, Brazil and 10 more
- Volunteers
- 47 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Acromegaly Due to Pituitary Adenoma, Hyperglycemia
Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Ketogenic Diet
Rationale: Pasireotide is a second line medical treatment for acromegaly that can add value for patients with insufficient control of disease on 1st generation SRL, or 1st generation SRL + pegvisomant.
- Conditions
- Acromegaly Due to Pituitary Adenoma, Hyperglycemia, Ketogenic Diet, Standard Care Control
- Trial name
- PasiAcroKeto (NCT07866846)
- Testing
- Ketogenic diet, Diabetes Medication
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Leiden University Medical Center
Acromegaly
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
This study will assess the efficacy of 8 months treatment of Sandostatin® LAR® High Dose monotherapy or Sandostatin® LAR® High Dose in combination either with growth hormone antagonist or dopamine agonist to control biochemical…
- Trial name
- HOSCAR (NCT01278342)
- Testing
- Sandostatin LAR, pegvisomant, cabergoline
- Where
- 20 sites in France, Italy and 3 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Surgical Versus Medical Treatment of Acromegaly
Evaluate biochemical differences in acromegalic patients treated with surgery versus somatostatin analogues (SMS) (after surgery or alone). Hypothesis: Treatment modality exhibit different biochemical responses in acromegaly.
- Trial name
- NCT01000090
- Where
- Denmark
- Volunteers
- 63 people
- Sponsor
- University of Aarhus
Acromegaly
Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
This study evaluated the safety and efficacy of an increased frequency of octreotide acetate injections or an increase in dose in partially responsive acromegalic patients with persistently uncontrolled disease.
- Trial name
- NCT00372697
- Testing
- Octreotide acetate 30 mg suspension
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas
Previous studies addressing preoperative somatostatin analogs (SSA) treatment and subsequent surgical cure rates are conflicting, reporting a benefit, or no difference between groups.
- Trial name
- NCT00993356
- Testing
- Preoperative lanreotide treatment, Transsphenoidal surgery
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Adrenal Insufficiency, Congenital Adrenal Hyperplasia
Dynamic Hormone Diagnostics in Endocrine Disease
The study will investigate 27 hour profiles of hormones in the subcutaneous tissue of healthy subjects and patients with Addison's, Congenital Adrenal Hyperplasia, Growth Hormone Deficiency, acromegaly, Cushings and Primary…
- Conditions
- Adrenal Insufficiency, Congenital Adrenal Hyperplasia, Cushing Syndrome, Growth Hormone Deficiency
- Trial name
- ultradian (NCT02934399)
- Testing
- 27 hour subcutaneous fluid sampling
- Where
- 4 sites in Greece, Norway and 2 more
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
Acromegaly
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
The purpose of the protocol is to evaluate the correlation between plasma lanreotide levels and Growth Hormone (GH)/Insulin Like Growth Factor 1 (IGF-1) dynamics and clinical improvement in patients with acromegaly treated with…
- Trial name
- NCT00517491
- Testing
- lanreotide (Autogel formulation)
- Where
- Mexico
- Sponsor
- Ipsen
Acromegaly
Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.
Prospective observational clinical, molecular, translational study aimed at identifying the main determinants and predictive factors of fragility fracture risck in acromegaly patients
- Trial name
- NCT06344650
- Testing
- Blood sample, Radiological tests, Questionnaires
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS San Raffaele